MPDL3280A

Phase 2Small molecule

CClovis Oncology, Inc.

MPDL3280A is one of 95 small molecule programs targeting Treatment. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

TreatmentActive, not recruiting

Lung CancerActive, not recruiting

ResistanceActive, not recruiting

TreatmentPhase 2

Active, not recruiting

Lung CancerPhase 2

Active, not recruiting

ResistancePhase 2

Active, not recruiting

Competition

Competitive Landscape

350 competitors in Treatment

#DrugCompanyPhaseTrials

Dexilant

Takeda

Preclinical

2 2

Alfenta

Jazz Pharmaceuticals

Preclinical

1 3

Niclocide

Bayer

Preclinical

1 4

Minipress

Pfizer

Preclinical

1 5

MPDL3280A

CClovis Oncology, Inc.

Phase 2

1 6

Hivid

CConrado Roberto Hoffmann Filho

Preclinical

6 7

Valium

Akero Therapeutics

Preclinical

2 8

Barhemsys

Tibotec Pharmaceuticals, Ireland

Preclinical

1 9

Clomid

Ferring

Preclinical

1 10

Aurlumyn

BBTG International Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 2Active, not recruiting

Lung Cancer

NCT02525757

Clinical

Trials by Indication[1]

Safety and Efficacy1 trial

A Phase 1b/2 Study of Safety and Efficacy of Rociletinib in Combination With MPDL3280A in Patients With Advanced or Metastatic EGFR-mutant NSCLC

Terminated·CClovis Oncology, Inc.·Phase 1/2·NCT02630186·3 enrolled

Treatment1 trial

MPDL3280A-treatment-IST-UMCG

Active, not recruiting·UUniversity Medical Center Groningen·Phase 2·NCT02478099·81 enrolled

Anal Carcinoma1 trial

A Study of mDCF in Combination or Not With Atezolizumab in Advanced Squamous Cell Anal Carcinoma

Completed·GGERCOR - Multidisciplinary Oncology Cooperative Group·Phase 2·NCT03519295·97 enrolled

Small Cell Lung Cancer1 trial

Carboplatin Plus Etoposide With or Without MPDL3280A in Untreated Extensive Stage Small Cell Lung Cancer

Terminated·GGiuseppe Giaccone·Phase 1/2·NCT02748889·1 enrolled

Non-Small Cell Lung Cancer1 trial

Phase 2 Study of MPDL3280A Combined With CDX-1401 in NY-ESO 1 (+) IIIB, IV or Recurrent Non-Small Cell Lung Cancer

Withdrawn·YYale University·Phase 2·NCT02495636

6 more indications

Resistance1 trial

Deciphering Antitumour Response and Resistance With INtratumour Heterogeneity

Active, not recruiting·UUniversity College, London·Phase 2·NCT02314481·50 enrolled

Metastatic NSCLC1 trial

A Pilot Study of MPDL3280A and HIGRT in Metastatic NSCLC

Completed·UUniversity of Michigan Rogel Cancer Center·Phase 1·NCT02463994·12 enrolled

Transitional Cell Carcinoma1 trial

Preoperative MPDL3280A in Transitional Cell Carcinoma of the Bladder

Completed·QQueen Mary University of London·Phase 2·NCT02662309·96 enrolled

Nab-paclitaxel1 trial

Neoadjuvant MPDL3280A, Nab-paclitaxel and Carboplatin (MAC) in NSCLC

Completed·—·Phase 2·NCT02716038·39 enrolled

Breast Cancer1 trial

Neoadjuvant Therapy in TRIPle Negative Breast Cancer With antiPDL1

Completed·FFondazione Michelangelo·Phase 3·NCT02620280·278 enrolled

Lung Cancer1 trial

DETERRED: PD-L1 blockadE To Evaluate the Safety of Lung CanceR Therapy Using Carboplatin, Paclitaxel, and Radiation CombinEd With MPDL3280A

Active, not recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT02525757·52 enrolled

Sources

References

[1]
ClinicalTrials.gov — 11 trial records for MPDL3280A. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — MPDL3280A compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for MPDL3280A. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Clovis Oncology, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: CClovis Oncology, Inc.

MPDL3280A

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Trials by Indication[1]

Safety and Efficacy1 trial

Treatment1 trial

Anal Carcinoma1 trial

Small Cell Lung Cancer1 trial

Non-Small Cell Lung Cancer1 trial

Resistance1 trial

Metastatic NSCLC1 trial

Transitional Cell Carcinoma1 trial

Nab-paclitaxel1 trial

Breast Cancer1 trial

Lung Cancer1 trial

References

Drug Info

Quick Facts

Related News